We are pleased to release the MUHC annual report for 2025-2026. It is available on the <<Resources>> page of the website. Below is a brief summary highlighting the key points and challenges of 2025-2026. Highlights •Four new or updated institutional guidelines published (ESBL/AmpC/CRE, urethritis/prostatitis/epididymo-orchitis, CDI update, automatic IV-to-PO conversion protocol). •Development of an Antibiotic guide with MUHC-specific AWaRe classification to support clinicians’ prescribing...

The ASP committee is happy to make available the new guide IV to PO! It covers situation in which a switch to PO is indicated for certain...

INESSS approved the TDM of Linezolid in May 2024 It is now available in the MUHC (via HSJ labs) The ASP committee is happy to publish a...